Company news

Neurizon Therapeutics Limited news in 2026

Neurizon Therapeutics Limited's news releases, calls and decks from 2026, newest first.

View company

First Regimen I patient enters Active Treatment Extension

November 12, 2026

R&D Facility Extension and Second Drawdown Completed

November 12, 2026

Change in substantial holding

November 10, 2026

Section 708A Cleansing Statement

November 8, 2026

Application for quotation of securities - NUZ

November 8, 2026

Application for quotation of securities - NUZ

November 8, 2026

Application for quotation of securities - NUZ

November 5, 2026

Investor webinar reminder and presentation

November 4, 2026

Notification of cessation of securities - NUZ

November 1, 2026

Withdrawal of Resolution 4 from Notice of AGM

November 1, 2026

Redemption of all remaining Obsidian convertible notes

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Proposed issue of securities - NUZ

November 1, 2026

Firm commitments to raise A$4.3m and announcement of SPP

November 1, 2026

Trading Halt

October 28, 2026

Trading Halt

October 28, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Appendix 4C & Quarterly Update

October 27, 2026

Notice of Annual General Meeting/Proxy Form

October 26, 2026

Change of AGM Date

October 22, 2026

Notification of cessation of securities - NUZ

October 13, 2026

Updated Investor Presentation and Webinar Reminder

October 6, 2026

FDA Type C Feedback, HEALEY trial potentially registrational

October 5, 2026

Dr Chris Bremer commences as Neurizon CEO

September 30, 2026

Change of Director's Interest Notice

September 16, 2026

Notification of cessation of securities - NUZ

September 15, 2026

Neurizon Announces Partial Redemption of Convertible Notes

September 9, 2026

Application for quotation of securities - NUZ

September 9, 2026

NIH funds Expanded Access Program for NUZ-001 in ALS

September 8, 2026

Neurizon Appoints Chief Executive Officer

September 6, 2026

Application for quotation of securities - NUZ

August 25, 2026

Appendix 4E and 2026 Annual Report

August 25, 2026

Appendix 4G and Corporate Governance Statement

August 25, 2026

Notification regarding unquoted securities - NUZ

August 24, 2026

Elanco representative appointed as Neurizon Board Observer

August 12, 2026

Neurizon Completes Initial Drawdown under R&D Facility

August 10, 2026

Neurizon Enters Strategic R&D Financing Facility

July 31, 2026

Appendix 4C & Quarterly Update

July 31, 2026

Melbourne investor briefing presentation

July 28, 2026

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

July 16, 2026

HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27

July 16, 2026

Neurizon executes long-term supply agreement with Elanco

June 16, 2026

HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule

June 11, 2026

HEALEY ALS Platform Trial Regimen I expands to 240 participants

May 27, 2026

HEALEY ALS Trial Regimen I Expands to 240 Participants

May 26, 2026

Ethics Approval Received for NUZ-001 Oral Liquid P1 Study

May 12, 2026

Placement of Entitlement Offer Shortfall

April 15, 2026

NUZ-001 Data Shows Multi-Pathway Protein Clearance

March 31, 2026

Neurizon announces leadership transition

March 15, 2026

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

February 26, 2026

Older news releases →

Decks in 2026